S
Serge Gauthier
Researcher at McGill University
Publications - 715
Citations - 61038
Serge Gauthier is an academic researcher from McGill University. The author has contributed to research in topics: Dementia & Disease. The author has an hindex of 93, co-authored 637 publications receiving 52775 citations. Previous affiliations of Serge Gauthier include Hamamatsu University School of Medicine & La Salle University.
Papers
More filters
Journal ArticleDOI
Suicidal ideation is common in autosomal dominant Alzheimer's disease at-risk persons.
Kok Pin Ng,Stéphane Richard-Devantoy,Josie-Anne Bertrand,Lai Jiang,Tharick A. Pascoal,Sulantha Mathotaarachchi,Joseph Therriault,Chathuri Yatawara,Nagaendran Kandiah,Celia M. T. Greenwood,Pedro Rosa-Neto,Serge Gauthier +11 more
TL;DR: To study the frequency of suicidal ideation and its association with clinical and neurobiological correlates among cognitively intact autosomal dominant Alzheimer's disease (ADAD) at‐risk individuals, a large number of at-risk individuals are surveyed.
Journal ArticleDOI
Motor symptoms in genetic frontotemporal dementia: developing a new module for clinical rating scales
Amy Macdougall,Georgia Peakman,Arabella Bouzigues,David M. Cash,Caroline V. Greaves,Rhian S Convery,John C. van Swieten,Lize C. Jiskoot,Harro Seelaar,Fermin Moreno,Raquel Sánchez-Valle,Robert Laforce,Caroline Graff,Mario Masellis,Carmela Tartaglia,James B. Rowe,S. Borroni,Elizabeth Finger,Matthis Synofzik,Daniela Galimberti,Rik Vandenberghe,Alexandre de Mendonça,Christopher C Butler,Alexander Gerhard,Simon Ducharme,Isabelle Le Ber,Isabel Santana,Florence Pasquier,Johannes Levin,Markus Otto,Sandro Sorbi,Jonathan D. Rohrer,Lucy L. Russell,Annabel Nelson,Martina Bocchetta,David L. Thomas,Emily Todd,Hanya Benotmane,Jennifer M. Nicholas,Kiran Samra,Rachelle Shafei,C. Timberlake,Thomas E. Cope,Timothy Rittman,Alberto Benussi,Enrico Premi,Roberto Gasparotti,Silvana Archetti,Stefano Gazzina,Valentina Cantoni,Andrea Arighi,Chiara Fenoglio,Giorgio G. Fumagalli,Vittoria Borracci,Giacomina Rossi,Giorgio Giaccone,Giuseppe Di Fede,Paola Caroppo,Pietro Tiraboschi,Sara Prioni,Veronica Redaelli,David F. Tang-Wai,Ekaterina Rogaeva,Miguel Castelo-Branco,Morris Freedman,Ron Keren,Sandra E. Black,Sara Mitchell,Christen Shoesmith,Robart Bartha,Rosa Rademakers,Jackie M. Poos,Janne M. Papma,Lucia A. A. Giannini,Rick van Minkelen,Yolande A.L. Pijnenburg,Benedetta Nacmias,Camilla Ferrari,Cristina Polito,Gemma Lombardi,Valentina Bessi,Michele Veldsman,Christin Andersson,Håkan Thonberg,Linn Öijerstedt,Vesna Jelic,Paul Thompson,Tobias Langheinrich,Albert Lladó,A. Antonelli,Jaume Olives,Mircea Balasa,Núria Bargalló,Sergi Borrego-Écija,Ana Verdelho,Carolina Maruta,Catarina Beatriz Silva Ferreira,Gabriel Miltenberger,Frederico Simões do Couto,Alazne Gabilondo,Ana Gorostidi,Jorge Villanua,Marta Cañada,Mikel Tainta,Miren Zulaica,Myriam Barandiaran,Patrícia Alves,Benjamin Bender,Carlo Wilke,Lisa Graf,Annick Vogels,Mathieu Vandenbulcke,Philip Van Damme,Rose Bruffaerts,Koen Poesen,Pedro Rosa-Neto,Serge Gauthier,Agnès Camuzat,Alexis Brice,Anne Bertrand,Aurélie Funkiewiez,Daisy Rinaldi,Dario Saracino,Olivier Colliot,Sabrina Sayah,Catharina Prix,Elisabeth Wlasich,Olivia Wagemann,Sandra V. Loosli,Sonja Schönecker,Tobias Hoegen,Jolina Lombardi,Sarah Anderl-Straub,Adeline Rollin,Grégory Kuchcinski,Maxime Bertoux,Thibaud Lebouvier,Vincent Deramecourt,Beatriz Santiago,Diana Duro,Maria João Leitão,Maria Rosário Almeida,Miguel Tábuas-Pereira,Sónia Afonso +143 more
TL;DR: In this paper , the authors investigated the optimal method of adding motor features to a clinical rating scale for frontotemporal dementia (FTD) and found that motor features are present in mutation carriers at all disease stages across all three genetic groups.
Journal ArticleDOI
Nonamyloid PET biomarkers and Alzheimer's disease: current and future perspectives
Lucas Porcello Schilling,Lucas Porcello Schilling,Antoine Leuzy,Eduardo R. Zimmer,Eduardo R. Zimmer,Serge Gauthier,Pedro Rosa-Neto +6 more
TL;DR: In the context of a growing shift toward early diagnosis and symptomatic and disease-modifying clinical trials, nonamyloid PET radiotracers will prove of use, and, potentially, contribute to improved therapeutic prospects for AD.
OtherDOI
Diagnosis of Alzheimer’s disease
Pedro Rosa-Neto,Jared Rowley,Antoine Leuzy,Sara Mohades,Monica Shin,Marina Dauar,Serge Gauthier +6 more
Journal ArticleDOI
How can we improve transfer of outcomes from randomized clinical trials to clinical practice with disease-modifying drugs in Alzheimer's disease?
TL;DR: The Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) appears to be the most reliable primary outcome for RCT at different stages of AD, with the Relevant Outcome Scale for Alzheimer's Disease (ROSA) as a suitable alternative.